Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Q3 2024 Management View CEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion yen, with a focus on the pharmaceutical business driving growth. Key contributors included ...

The therapy is already approved in Japan, China, the US, South Korea and the UK. The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the therapy for approval in ...

and four months since the China launch, and Leqembi is in the midst of market introduction," said Eisai in its update. "Although there were some delays in the progression of sales results in the ...

TOKYO -- Japanese drugmaker Eisai will make its Alzheimer's disease ... with the company planning to later roll out home use in China and India. "The new formulation will be a game changer in ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday.

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

The U.S. Food and Drug Administration in 2023 approved Leqembi, which is also approved in the U.K., Japan, China and several other countries. Japan's Eisai serves as the lead for Leqembi's ...

2023. Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen. Last accessed: October 2024. The Pharma Letter. 2024. Brief - Alzheimer drug Leqembi now approved in China. Last ...

Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...